LON:NCYT

Novacyt Final Earnings Results & Report

Novacyt logo
GBX 35.90 -0.50 (-1.37%)
As of 03:23 AM Eastern

Novacyt reported Final earnings on April 30, 2026. The company reported EPS of -GBX 33, while revenue was £20.03 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Novacyt EPS Results

Actual EPS
-GBX 33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novacyt Revenue Results

Actual Revenue
£20.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Novacyt Final Earnings FAQ

Novacyt (LON:NCYT) reported earnings of -GBX 33 per share for Final. The report was announced on Thursday, April 30, 2026.

Novacyt reported revenue of £20.03 million for Final.

Novacyt Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Novacyt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novacyt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novacyt and other key companies, straight to your email.

About Novacyt

Novacyt (LON:NCYT) is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com

View Novacyt Profile